Site-Selective Antibody Labeling for Homogeneous ADC Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing antibody-drug conjugates lack site-selectivity and homogeneity, leading to reduced antibody binding affinity and difficulties in quality control, and often require genetic modification of antibodies.
Innovation Solution
A method using a conjugation-mediating protein with incorporated non-canonical amino acids and a pyridinium oxime derivative for site-specific synthesis of antibody-drug conjugates, applicable to native antibodies without additional modifications to existing production systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If chemical incorporation method utilizing lysine or cysteine is used, then the conjugation process is simple and existing antibodies can be used without modification, but the site selectivity is poor and homogeneity is low
Solution Approach 1:
The invention changes the chemical parameters of the antibody by introducing non-canonical amino acids with specific functional groups (azide, alkyne, tetrazine) at defined positions, transforming the conjugation process from non-specific chemical reactions to highly selective bioorthogonal reactions with controlled kinetics and specificity
Solution Approach 2:
The invention applies local quality by incorporating non-canonical amino acids at specific local positions on the antibody molecule (e.g., Fc region, Fab region, or N-/C-terminus), creating sites with unique chemical properties that enable selective conjugation while maintaining the rest of the antibody structure unchanged
2Manufacturing precision
If site-specific incorporation methods utilizing enzyme are used, then site selectivity and homogeneity are improved, but genetic modification is required to incorporate amino acid sequences recognizable by the enzyme
Solution Approach 1:
The invention uses non-canonical amino acids as intermediaries that bridge the gap between existing antibody production systems and site-specific conjugation capabilities. These ncAAs can be incorporated through genetic code expansion in existing systems without requiring additional enzyme recognition sequences, serving as universal handles for bioorthogonal chemistry
Solution Approach 2:
The invention creates a universal platform where non-canonical amino acids with different reactive groups (azide, alkyne, tetrazine) can be incorporated at various positions on different antibody types, enabling a single conjugation chemistry approach to work across multiple antibody platforms without system-specific modifications
3Manufacturing precision
If non-canonical amino acids are incorporated into binding protein and pyridinium oxime derivative is conjugated, then site-selective and homogeneous ADC synthesis is achieved without genetic modification of antibody production systems
Solution Approach 1:
The invention extracts the complexity of site-specific conjugation from the antibody production system itself and separates it into a post-production step. The antibody is produced using standard systems, then purified and subjected to the ncAA incorporation and pyridinium oxime conjugation process, isolating the complex chemistry from the biological production
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables high-yield, homogeneous synthesis of antibody-drug conjugates with site-selective drug incorporation, maintaining antibody efficacy and facilitating quality control.
Implementation Method 1
proximity effect-based site-selective antibody labeling
Data Source
Figure 1
Figure 2a
Figure 2b
AI summary
The present invention relates to a method for the synthesis of an antibody-drug conjugate using proximity effect-based site-selective antibody labeling. Provided according to the present invention may be a method for the synthesis of an antibody-drug conjugate by site-selectively introducing a drug into an antibody using a pyridinium oxime derivative (labeling mediator protein) introduced into a binding protein containing a non-standard amino acid.